报告题目：Pushing Molecular Optical Imaging Probes Towards Clinical Translation（推动分子光学成像探针走向临床应用）
Homepage:https://personal.ntu.edu.sg/kypu/index.html
时间：2023年8月26日（星期六）15:00-16:30
地点：东区会议中心二楼报告厅
欢迎感兴趣的师生前往！
Biography:Dr. Kanyi Pu is an Associate Professor in School of Chemistry, Chemical Engineering and Biotechnology (CCEB) and Lee Kong Chian School of Medicine at Nanyang Technological University. He is a Singapore National Research Foundation (NRF) Investigator, a highly cited researcher listed by Clarivate Analytics, Fellow of the Royal Society of Chemistry (FRSC), and the associate editor for ACS Applied Polymer Materials and Biomaterials Research. Dr. Pu’s research interest focuses on the biophotonics of organic semiconducting materials, including development of (i) molecular optical imaging probes for early diagnosis, (ii) smart phototherapeutics for cancer therapy, and (iii) nanotransducers for photoregulation.
With a h-index of 107, he has won a number of awards for his creative work, including Biomaterials Science Lectureship Award, distinguished lectureship award from the Chemistry Society of Japan, Wiley award for contribution in bioscience, young innovator award in nanobiotechnology by Nano Research, and young investigator travel award by WMIC. He is the member of board of directors of Chinese American Society of Nanomedicine and Nanobiotechnology (CASNN). He also sits on the editorial advisory board of more then 17 top journals such as Chemical Society Reviews, Advanced Functional Materials, Biomaterials, Small, etc.
Abstract: Molecular optical imaging plays a crucial role in biology and medicine. However, the strong tissue autofluorescence and shallow tissue penetration of optical imaging not only compromise its sensitivity and specificity but also limit its clinical translation. In this talk, I will introduce our approaches (afterglow imaging and artificial urinary biomarkers) to tackle the challenges to advance the clinical translation of molecular optical probes. First, I will introduce molecular afterglow probes with long-lasting luminescence after removal of light excitation for ultrasensitive in vivo imaging. Molecular afterglow probes have the signal to background ratio more than two orders of magnitude higher than NIR fluorescence, allowing for sensitive detection of tiny peritoneal metastatic tumors and monitoring therapeutic outcome. Second, I will discuss how to design renal-clearable optical probes as artificial urinary biomarkers for early diagnosis of acute kidney injury (AKI) and allograft rejection. Molecular renal probes (MRPs) are developed to specifically activate their NIR/chemiluminescence signals towards the biomarkers of AKI or immune cells, followed by rapid renal clearance for urine tests. MRPs thus can act as artificial urinary biomarkers to bypass the in vivo imaging challenges, permitting optical urinalysis that outperforms typical clinical/preclinical assays. These studies provide the basis for an entirely new class of molecular optical probes with ultrahigh sensitivity and high translational potential for disease diagnosis and prognosis.